Costs of treating and preventing nausea and vomiting in patients receiving chemotherapy

Journal of Clinical Oncology

Volumn 17, Issue 1, 1999, Pages 344-351

  Stewart, David J ^a   Dahrouge, Simone ^a   Coyle, Doug ^a   Evans, William K ^a  

^a OTTAWA REGIONAL CANCER CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ONDANSETRON;

ADULT; ARTICLE; COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG COST; FEMALE; HEALTH CARE COST; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; PRIORITY JOURNAL; VOMITING;

EID: 0032895607     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.1999.17.1.344     Document Type: Article

References (18)

1. Roila F, Tonato M, Del Favero A: Prevention of chemotherapy-induced emesis: The state of the art. Dig Dis 11:343-353, 1993
2. Tonato M, Roila F, Del Favero A, et al: Antiemetics in cancer chemotherapy: Historical perspective and current state of the art. Support Care Cancer 2:150-160, 1994
3. Butcher ME: Global experience with ondansetron and future potential. Oncology 50:191-197, 1993
4. Soukop M, McQuade B, Hunter E, et al: Ondansetron compared with metoclopramide in the control of emesis and quality of life during repeated chemotherapy for breast cancer. Oncology 49:295-304, 1992
5. Laplanche A, Gerondeau N: Role of ondansetron in oncology. Bull Cancer 80:568-76, 1993
6. Walton SC, Koenig TJ: Effectiveness and economy of low-dose ondansetron. Am J Health Syst Pharm 52:546-547, 1995
7. Nolte J, Lucarelli C, Baltzer L, et al: Development, implementation and assessment of antiemetic guidelines. Proc Am Soc Clin Oncol 14:A1735, 1995 (abstr)
8. Berard CM, Mahoney CD: Cost-reducing treatment algorithms for antineoplastic drug-induced nausea and vomiting. Am J Health Syst Pharm 52:1879-1885, 1995
9. Dranitsaris G, Warr D, Puodziunas A: A randomized trial of the effects of pharmacist intervention on the cost of antiemetic therapy with ondansetron. Support Care Cancer 3:183-189, 1995
10. Vermeulen LC Jr, Matsuszewski KA, Ratko TA, et al: Evaluation of ondansetron prescribing in US academic medical centers. Arc Intern Med 154:1733-1740, 1994
11. Cox F, Hirsch J: Ondansetron: A cost effective advance in anti-emetic therapy. Oncology 50:186-190, 1993
12. Buxton MJ, O'Brien BJ: Economic evaluation of ondansetron: Preliminary analysis using clinical data prior to price setting. Br J Cancer 66:64-67, 1992 (suppl 19)
13. Tannenberger S. Lelli G. Martoni A: The antiemetic efficacy and the cost-benefit ratio of ondansetron calculated with a new approach to health technology assessment (real cost-benefit index). J Chemother 4:326-331, 1992
14. Cunningham D, Gore M, Davidson N, et al: The real costs of emesis: An economic analysis of ondansetron vs metoclopramide in controlling emesis in patients receiving chemotherapy for cancer. Eur J Cancer 29A:303-306, 1993
15. Ballatori E, Roila F, Berto P, et al: Cost efficacy analysis of two antiemetic treatments: The Italian experience from hospital perspective. Proc Am Soc Clin Oncol 13:A1615, 1994 (abstr)
16. Jaakkimainen L, Goodwin PJ, Pater J, et al: Counting the costs of chemotherapy in a National Cancer Institute of Canada randomized trial in nonsmall-cell lung cancer. J Clin Oncol 8:1301-1309, 1990
17. Rapp E, Pater JL, Willan A, et al: Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer: Report of a Canadian multicenter randomized trial. J Clin Oncol 6:633-641, 1988
18. Stewart DJ: New and old cancer therapies: Access, cost, and cost effectiveness. Oncol Advisor 2:3-8, 1994